30 Day Survey

Submitted by Jack Attack on

*
Please use the scale: 1=Much less, 2=Less, 3=The same amount, 4=More, 5=Much more, N/A=Not applicable to me
12345NA
Review the science of PCSK9 inhibitor therapeutics for patients with dyslipidemia.
Analyze extended clinical trial data for PCSK9 inhibitor therapeutics.
Formulate personalized treatment plans to incorporate PCSK9 inhibitors to reduce risk and improve outcomes for patients with dyslipidemia.
*
Please use the scale: 1=Much less, 2=Less, 3=The same amount, 4=More, 5=Much more, N/A=Not applicable to me
12345NA
Understand best practice strategies for administering PCSK9 therapeutics when treating patients with dyslipidemia
Integrate newer scientific knowledge into personalized treatment plans for patients with dyslipidemia
Utilize the multidisciplinary team approach to educate and improve patient adherence